Abstract
Drug eruptions often have nonspecific clinical findings, and the evaluation of the probability of an eruption being a drug-induced event is difficult. A few types of drug eruption do not present such problems, and the fixed drug eruption is one of those whose clinical findings are specific enough to allow a diagnosis.
The fixed drug eruption is a commonly reported type of drug eruption. The incidence of fixed drug eruptions has tended to increase, although the overall number of drug eruption cases has decreased. This is one of the reasons why fixed drug eruptions are familiar to dermatologists.
The most characteristic findings of a fixed drug eruption are recurrence of similar lesions at the same sites and healing with residual hyperpigmentation. The residual hyperpigmentation serves as an indicator of site recognition. Diagnosis is not always easy; for example, as is the case for nonpigmenting fixed drug eruptions, which do not have any residual hyperpigmentation. The development of molecular biology may help to clarify the pathogenesis of fixed drug eruptions, but the reason for their recurrence on the same sites is still unknown.
Identification of the causative drug or drugs is essential for the management of fixed drug eruptions, as it is for other drug eruptions. The causative drug or drugs and cross-reactants should be avoided to prevent recurrence. To date, rechallenge is the most reliable method of identifying causative drugs, but increasingly the use of skin tests has gained the attention of investigators. The validity and the problems of skin tests are discussed, and an approach to the clinical management of fixed drug eruptions is presented.
Similar content being viewed by others
References
Arndt K.A., Jick H. Rates of cutaneous reactions to drugs. A report from the Boston Collaborative Drug Surveillance Program. JAMA 1976; 235: 918–922
Bigby M., Jick S., Jick H., et al. Drug-induced cutaneous reactions. A report from the Boston Collaborative Drug Surveillance Program on 15438 consecutive inpatients, 1975 to 1982. JAMA 1986; 256: 3358–3363
Kauppinen K., Alanko K. Oral provocation: uses. Semin Dermatol 1989; 8: 187–191
Langeland J. Exanthema fixum due to ultraviolet radiation. Acta Derm Venereol 1982; 62: 169–171
Del Rio E., Guimaraens D., Aguilar A., et al. Fixed exanthema induced by ultraviolet radiation. Dermatology 1996; 193: 54–55
Kelso J.M. Fixed food eruption. J Am Acad Dermatol 1996; 35: 638–639
Orchard D.C., Varigos G.A. Fixed drug eruption to tartrazine. Australas J Dermatol 1997; 38: 212–214
Yanguas I., Oleaga J.M., Gonzalez-Guemes M., et al. Fixed food eruption caused by lentils. J Am Acad Dermatol 1998; 38: 640–641
Puavilai S., Choonhakarn C. Drug eruptions in Bangkok: a 1-year study at Ramathibodi Hospital. Int J Dermatol 1998; 37: 747–751
Mahboob A., Haroon T.S. Drugs causing fixed eruptions: a study of 450 cases. Int J Dermatol 1998; 37: 833–838
Stubb S., Heikkila H., Kauppinen K. Cutaneous reactions to drugs: a series of in-patients during a five-year period. Acta Derm Venereol (Stockh) 1994; 74: 289–291
Sharma V.K., Dhar S., Clinical pattern of cutaneous drug eruption among children and adolescents in North India. Ped Dermatol 1995; 12: 178–183
Hunziker Th., Kunzi U.-P., Braunschweig S., et al. Comprehensive hospital drug monitoring (CHDM): adverse skin reactions, a 20-year survey. Allergy 1997; 52: 388–393
Bigby M., Stern R.S., Arndt K.A. Allergic cutaneous reactions to drugs. Prim Care 1989; 16: 713–727
Kuligowski M.E., Chang A., Rathi R. Multiple fixed drug eruption due to ibuprofen. Contact Dermatitis 1991; 25: 259–260
Sehgal V.N., Bhattacharya S.N. Multiple fixed drug eruption (FDE) following continuous cotrimoxazole (TMP + SMZ) therapy. J Dermatol 1997; 24: 410–411
Mizukawa Y., Shiohara T. Fixed drug eruption presenting as erythema dyschromicum perstans: a flare without taking any medications. Dermatology 1998; 197: 383–385
Palungwachira P., Palungwachira P. Fixed drug eruption due to atenolol: a case report. J Med Assoc Thai 1999; 82: 1158–1161
Inserra D.W., Camisa C. Erythema multiforme-like fixed drug eruption. Cutis 1989; 44: 223–225
Sowden J.M., Smith A.G. Multifocal fixed drug eruption mimicking erythema multiforme. Clin Exp Dermatol 1990; 15: 387–388
Baird B.J., De Villez R.L. Widespread bullous fixed drug eruption mimicking toxic epidermal necrolysis. Int J Dermatol 1988; 27: 170–174
Sigal-Nahum M., Konqui A., Gaulier A., et al. Linear fixed drug eruption. Br J Dermatol 1988; 118: 849–851
Ozkaya-Bayazit E., Baykal C. Trimethoprim-induced linear fixed drug eruption. Br J Dermatol 1997; 137: 1028–1029
Grosshans E., Marot L. Blaschkitis in adults. Ann Dermatol Venereol 1990; 117: 9–15
Guin J.D., Haynie L.S., Jackson D., et al. Wandering fixed drug eruption: a mucocutaneous reaction to acetaminophen. J Am Acad Dermatol 1987; 17: 399–402
Shelley W.B., Shelley E.D. Nonpigmenting fixed drug eruption as a distinctive reaction pattern: examples caused by sensitivity to pseudoephedrine hydrochloride and tetrahydrozoline. J Am Acad Dermatol 1987; 17: 403–407
Benson P.M., Giblin W.J., Douglas D.M. Transient, nonpigmenting fixed drug eruption caused by radiopaque contrast media. J Am Acad Dermatol 1990; 23: 379–381
Dereure O., Guilhou J.J. Nonpigmenting fixed drug eruption: a new case due to betahistine. Dermatology 1996; 193: 248–250
Yeo S.N., Kang SJ, Lee A.Y. Nonpigmenting fixed drug eruption to etodolac [in Korean]. Korean J Dermatol 1999; 37(5): 673–675
Roholt N.S., Lapiere J.C., Traczyk T., et al. A nonscarring sublamina densa bullous drug eruption. J Am Acad Dermatol 1995; 32: 367–371
Thankappan T.P., Zachariah J. Drug-specific clinical pattern in fixed drug eruptions. Int J Dermatol 1991; 30: 867–870
Sharma V.K., Dhar S., Gill A.N. Drug related involvement of specific sites in fixed eruptions: a statistical evaluation. J Dermatol 1996; 23: 530–534
Jain V.K., Dixit V.B., Archana. Fixed drug eruption of the oral mucous membrane. Ann Dent 1991; 50: 9–11
Kanwar A.J., Dhar S., Ghosh S., et al. Mucosal fixed drug eruption. Dermatology 1994; 188: 171
Masu S., Seiji M. Pigmentary incontinence in fixed drug eruption. Histologic and electron microscopic findings. J Am Acad Dermatol 1983; 8: 525–532
Stritzler C., Kopf A.W. Fixed drug eruption caused by 8-chlorotheophylline in Dramamine® with clinical and histologic studies. J Invest Dermatol 1960; 34: 319–330
Van Voorhees A., Stenn K.S. Histological phases of Bactrim-induced fixed drug eruption. The report of one case. Am J Dermatopathol 1987; 9: 528–532
De Dobbeleer G., Achten G. Fixed drug eruption: ultrastructural study of dyskeratotic cells. Br J Dermatol 1977; 96: 239–244
Visa K., Kayhko K., Stubb S., et al. Immunocompetent cells of fixed drug eruption. Acta Derm Venereol 1987; 67: 30–35
Hindsen M., Christensen O.B., Gruic V., et al. Fixed drug eruption: an immunohistochemical investigation of the acute and healing phase. Br J Dermatol 1987; 116: 351–360
Komatsu T., Moriya N., Shiohara T. T cell receptor (TCR) repertoire and function of human epidermal T cells: restricted TCR V alpha-V beta genes are utilized by T cells residing in the lesional epidermis in fixed drug eruption. Clin Exp Dermatol 1996; 104: 343–350
Teraki Y., Moriya N., Shiohara T. Drug-induced expression of intercellular adhesion molecule-1 on lesional keratinocytes in fixed drug eruption. Am J Pathol 1994; 145: 550–560
Shiohara T., Nickoloff B.J., Sagawa Y., et al. Fixed drug eruption. Expression of epidermal keratinocyte intercellular adhesion molecule-1(ICAM-1). Arch Dermatol 1989; 125: 1371–1376
Yamauchi R., Morita A., Tsuji T. Fixed drug eruption caused by iopamiol, a contrast medium. J Dermatol 1997; 24: 243–245
Alanko K., Stubb S., Reitamo S. Topical provocation of fixed drug eruption. Br J Dermatol 1987; 116: 561–567
Alanko K. Topical provocation of fixed drug eruption. A study of 30 patients. Contact Dermatitis 1994; 31: 25–27
Ozkaya-Bayazit E., Bayazit H., Ozarmagan G. Topical provocation in 27 cases of cotrimoxazole-induced fixed drug eruption. Contact Dermatitis 1999; 41: 185–189
Lee A.Y. Topical provocation in 31 cases of fixed drug eruption: change of causative drugs in 10 years. Contact Dermatitis 1998; 38: 258–260
Lee A.Y., Lee Y.S. Provocation tests in a chlormezanone-induced fixed drug eruption. DICP 1991; 25: 604–605
Watanabe H., Sueki H., Nakada T., et al. Multiple fixed drug eruption caused by iomeprol (lomeron), a nonionic contrast medium. Dermatology 1999; 198: 291–294
Gonzalo Garijo M.A., Bobadilla Gonzalez P. Cutaneous reaction to naproxen. Allergol Immunopathol (Madr) 1996; 24: 89–92
De Barrio M., Tornero P., Prieto A., et al. Recurrent fixed drug eruption caused by citiolone. J Invest Allergol Clin Immunol 1997; 7: 193–194
Garcia J.C., Torre F., Sanchez M., et al. Fixed drug eruption induced by lidocaine and patch testing. J Invest Allergol Clin Immunol 1997; 7: 127–128
Jimenez I., Anton E., Picans I., et al. Fixed drug eruption from amoxycillin. Allergol Immunopathol (Madr) 1997; 25: 247–248
Alanko K. Patch testing in cutaneous reactions caused by carbamazepine. Contact Dermatitis 1993; 29: 254–257
Navarro J.A., Audicana M.T., Villas F., et al. Intradermal testing of fixed drug eruption. Allergy 1996; 51: 963–964
Rietschel R.L., Fowler Jr J.F. The role of patch testing. In: Fisher’s contact dermatitis. 4th ed. Baltimore: Williams & Wilkins, 1995: 11–32
Fujimoto Y., Hayakawa R., Suzuki M., et al. Fixed drug eruption due to allylisopropylacetylurea. Contact Dermatitis 1993; 28: 282–284
Smola H., Kruppa A., Hunzelmann N, et al. Identification of dimenhydrinate as the causative agent in fixed drug eruption using patch-testing in previously affected skin. Br J Dermatol 1998; 138: 920–921
Bruynzeel D.P., Maibach H.I. Patch testing in systemic drug eruptions. Clin Dermatol 1997; 15: 479–484
Gomez B., Sastre J., Azofra J., et al. Fixed drug eruption. Allergol Immunopathol (Madr) 1985; 13: 87–91
Kauppinen K., Kariniemi A.-L. Clinical manifestations and histological characteristics. In: Kauppinen K., Alanko K., Hannuksela M., et al., editors. Skin reactions to drugs. Boca Raton: CRC Press, 1998: 30–31
Sehgal V.N., Rege V.L., Kharangate V.N. Fixed drug eruption caused by medications: a report from India. Int J Dermatol 1978; 7: 78–81
Kanwar A.J., Bharija S.C., Singh M., et al. Ninety eight fixed drug eruptions with provocation tests. Dermatologica 1988; 177: 274–279
Bharija S.C., Belhaj M.S. Fixed drug eruption due to cotrimoxazole. Australas J Dermatol 1989; 30: 43–44
Morelli J.G., Tay Y.-K., Rogers M., et al. Fixed drug eruptions in children. J Pediatr 1999; 134: 365–367
Alanko K., Stubb S., Kauppinen K. Cutaneous drug reactions: clinical types and causative agents. A five-year survey of in-patients (1981-1985). Acta Derm Venereol (Stockh) 1989; 69: 223–226
Sehgal V.N., Gangwani O.P. Fixed drug eruption. Current concepts. Int J Dermatol 1987; 26: 67–74
Browne S.G. Fixed eruption in deeply pigmented subjects: clinical observations on 350 patients. BMJ 1964; 2: 1041–1044
Tham S.N., Kwok Y.K., Chan H.L. Cross-reactivity in fixed drug eruptions to tetracyclines. Arch Dermatol 1996; 132: 1134–1135
Bargman H. Lack of cross-sensitivity between tetracycline, doxycycline, and minocycline with regard to fixed drug sensitivity to tetracycline. J Am Acad Dermatol 1984; 11: 900–901
Ordoqui E., De Barrio M., Rodriguez V.M., et al. Cross-sensitivity among oxicams in piroxicam-caused fixed drug eruption: two case reports. Allergy 1995; 50: 741–744
Mishra D., Mobashir M., Zaheer M.S. Fixed drug eruption and cross-reactivity between tinidazole and metronidazole. Int J Dermatol 1990; 29: 740
Thami G.P., Kanwan A.J. Fixed drug eruption due to metronidazole and tinidazole without cross-sensitivity to secnidazole. Dermatology 1998; 196: 368
Pasricha J.S., Shukla S.S. Independent lesions of fixed eruption due to two unrelated drugs in the same patient. Br J Dermatol 1979; 101: 361–362
Chan H.L., Tan K.C. Fixed drug eruption to three anticonvulsant drugs: an unusual case of polysensitivity. J Am Acad Dermatol 1997; 36: 259
Bhargava P., Kuldeep C.M., Mathur N.K. Polysensitivity and familial occurrence in fixed drug eruption. Int J Dermatol 1997; 36: 236
Kelso J.M., Keating R.M. Successful desensitization for treatment of a fixed drug eruption to allopurinol. J Allergy Clin Immunol 1996; 97: 1171–1172
Umpierrez A., Cuesta-Herranz J., De Las Heras M., et al. Successful desensitization of a fixed drug eruption caused by allopurinol. J Allergy Clin Immunol 1998; 101: 286–287
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lee, AY. Fixed Drug Eruptions. Am J Clin Dermatol 1, 277–285 (2000). https://doi.org/10.2165/00128071-200001050-00003
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200001050-00003